Across TCGA pan-cancer cohorts, RNU6-356P RNA is linked to patient survival in 5 of 34 cancer types, making it the most broadly survival-associated RNU6-356P data layer.

The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher RNU6-356P RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated RNU6-356P expression acts as an unfavorable survival marker, although some lineages such as STAD and ESCA show a favorable association.

CESC, UCEC, and ACC are the cancer types where RNU6-356P RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CESC	DFS	Tertile	All	0.053	0.823	<.001	126	view →
UCEC	OS	Tertile	All	0.169	0.685	<.001	108	view →
ACC	OS	Tertile	All	0.188	0.820	<.001	54	view →
STAD	OS	Tertile	II,III,IV	0.875	0.635	.030	9	view →
ESCA	DFS	Tertile	III,IV	0.706	0.273	.042	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: RNU6-356P tumor-vs-normal RNA expression · all RNU6-356P data types